Display options
Cite
Cho IC, Chung HS, Cho KS, et al. Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat. 2010;42(3):157-62doi: 10.4143/crt.2010.42.3.157.
Cho, I. C., Chung, H. S., Cho, K. S., Kim, J. E., Joung, J. Y., Seo, H. K., Chung, J., Park, W. S., Hong, E. K., & Lee, K. H. (2010). Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer research and treatment, 42(3), 157-62. https://doi.org/10.4143/crt.2010.42.3.157
Cho, In-Chang, et al. "Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis." Cancer research and treatment vol. 42,3 (2010): 157-62. doi: https://doi.org/10.4143/crt.2010.42.3.157
Cho IC, Chung HS, Cho KS, Kim JE, Joung JY, Seo HK, Chung J, Park WS, Hong EK, Lee KH. Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat. 2010 Sep;42(3):157-62. doi: 10.4143/crt.2010.42.3.157. Epub 2010 Sep 30. PMID: 20948921; PMCID: PMC2953779.
Copy Download .nbib Format: NLM
Share it on

Cancer Res Treat. 2010 Sep;42(3):157-62. doi: 10.4143/crt.2010.42.3.157. Epub 2010 Sep 30.

Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis.

Cancer research and treatment

In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee

Affiliations

  1. Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea.

PMID: 20948921 PMCID: PMC2953779 DOI: 10.4143/crt.2010.42.3.157

Abstract

PURPOSE: The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

MATERIALS AND METHODS: This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

RESULTS: Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

CONCLUSION: Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Keywords: B-cell leukemia/lymphoma 2; Prostatectomy; Prostatic neoplasms; Proto-oncogene proteins; Recurrence

References

  1. J Clin Oncol. 2005 Aug 1;23(22):4975-9 - PubMed
  2. J Natl Cancer Inst. 1998 May 20;90(10):766-71 - PubMed
  3. Am J Pathol. 1995 Jun;146(6):1368-75 - PubMed
  4. J Urol. 2003 Jul;170(1):78-81 - PubMed
  5. Am J Surg Pathol. 1996 Mar;20(3):286-92 - PubMed
  6. Eur Urol. 1999;35(5-6):399-407 - PubMed
  7. Adv Anat Pathol. 2002 Mar;9(2):115-28 - PubMed
  8. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8910-4 - PubMed
  9. J Clin Oncol. 1999 May;17(5):1499-507 - PubMed
  10. Semin Urol Oncol. 1998 Aug;16(3):137-44 - PubMed
  11. Cancer Surv. 1992;15:105-18 - PubMed
  12. Urology. 2004 Oct;64(4):765-71 - PubMed
  13. Cancer Res. 1995 Oct 1;55(19):4438-45 - PubMed
  14. Hum Pathol. 1998 Sep;29(9):949-54 - PubMed
  15. BJU Int. 2002 Jan;89(1):27-32 - PubMed
  16. Int J Urol. 2005 Apr;12(4):340-5 - PubMed
  17. Oncol Rep. 2003 Jan-Feb;10(1):223-8 - PubMed
  18. Am J Pathol. 1993 Aug;143(2):390-400 - PubMed
  19. J Urol. 1996 Oct;156(4):1511-6 - PubMed
  20. J Urol. 1999 Dec;162(6):2040-5 - PubMed
  21. J Urol. 2004 Jul;172(1):137-40 - PubMed
  22. Cancer Res. 1992 Dec 15;52(24):6940-4 - PubMed
  23. Am J Pathol. 1991 Nov;139(5):989-93 - PubMed

Publication Types